KSRに結合したMEKにおけるトラメチニブの作用の構造的基礎
PubMedで要約を見る
まとめ
この要約は機械生成です。新しい研究は,MEK阻害剤がKSRに結合する方法を明らかにし,薬剤耐性を克服することで,より安全で効果的ながん治療につながる新しいメカニズムを発見しました.
科学分野
- 生物化学
- 分子生物学
- 薬物の発見
背景
- ミトゲン活性化タンパク質キナーゼ (MEK) は,腫瘍学,免疫療法,老化研究における重要な標的である.
- 現在のMEK阻害剤は,標的毒性および薬剤耐性による制限に直面しています.
- 生理学的な複合体におけるMEKの機能を理解することは,改善された治療法の開発に不可欠です.
研究 の 目的
- 生理学的な複合体内のMEK阻害の構造的基礎を解明する.
- トラメチニブを含むMEK阻害剤の結合メカニズムを,KSRとの複合体で調査する.
- 次の世代のMEK阻害剤の設計にインパクトを与えるため,有効性が向上し,抵抗性が低下します.
主な方法
- KSRと様々なMEK阻害剤に結合するMEKの構造を決定するために,X線結晶学を用いた.
- 薬物と標的の相互作用と結合運動の分析が行われました.
- 構造的な洞察に基づいた新しい阻害剤,トラメチグルの開発.
主要な成果
- トラメチニブがMEKインターフェイスでKSRを誘導する予期せぬ結合モードをX線結晶構造で明らかにした.
- KSRはMEK阻害体のアロステリックポケットを改造し,結合と薬の停留時間に影響を与えます.
- トラメチニブがKSR- MEKに結合すると,保護されたインターフェース残留物によって関連するRAF- MEK複合体が破壊される.
結論
- この研究は,MEKのインターフェースポケットの可塑性と,KSRとの相互作用を明らかにしています.
- この発見は,より安全で効果的なMEK阻害剤を設計するための分子テンプレートを提供します.
- 開発されたトラメチグルは,MEK阻害に対する適応抵抗を制限する戦略を示しています.
関連する概念動画
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

